Press release
Asthma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND
Explore our latest breakthroughs in Asthma Research. Learn more about our innovative pipeline today! @ Asthma Pipeline Outlook [https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Asthma Pipeline Report
* In April 2025, Areteia Therapeutics announced a study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.
* In April 2025, Chiesi Farmaceutici S.p.A . conducted a study is to evaluate the amount of the study drug, CHF6001, in the blood of adolescent patients with asthma in comparison to adult patients with asthma after a single oral dose of the study drug, CHF 6001.
* In April 2025, AstraZeneca organized a study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication.
* DelveInsight's Asthma pipeline report depicts a robust space with 80+ active players working to develop 90+ pipeline therapies for Asthma treatment.
* The leading Asthma Companies such as GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Oneness Biotech Co., Ltd., Arrowhead Pharmaceuticals, Areteia Therapeutics, Jiangsu HengRui Medicine, SinoMab BioScience Ltd, Incyte Corporation, CSPC ZhongQi Pharmaceutical, Advagene Biopharma Co. Ltd., Beijing Kanova Biopharmaceutical, Inmunotek, Roche, Sanofi, ARS Pharmaceuticals , and others.
* Promising Asthma Therapies such as HSK31858, Dexpramipexole Dihydrochloride, Benralizumab, Dupilumab, Rocatinlimab, Mepolizumab , and others.
Stay informed about the cutting-edge advancements in Asthma treatments. Download for updates and be a part of the revolution in care @ Asthma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Asthma Emerging Drugs Profile
* GSK3511294: GlaxoSmithKline
GSK'294 is an anti-IL-5 monoclonal antibody currently in development for the treatment of severe eosinophilic asthma. It is a distinct, new biologic entity and has been engineered for high affinity and long-acting suppression of IL-5 function. IL-5 is the major cytokine responsible for the proliferation, activation and survival of eosinophils, making it a proven treatment target for severe asthma patients with higher levels of eosinophils. In patients with severe eosinophilic asthma, targeted anti-IL-5 therapies are a well-established and effective treatment approach. GSK3511294 is currently being investigated in Phase III stage of Clinical trial evaluation for the treatment of Asthma.
* TQC2731: Chia Tai Tianqing Pharmaceutical Group
TQC2731, belongs to the class of Antiasthmatic. These anti-inflammatory drugs are the most effective and commonly used long-term control medications for asthma. They reduce swelling and tightening in the airways. An Antiasthmatic and antiallergic agent also prevents mast cell release of histamine and formation of other mediators (leukotrienes) of anaphylaxis by inhibiting degranulation after contact with antigens. These helps prevent symptoms of asthma, allergic rhinitis, mastocytosis, and exercise-induced bronchospasm.TQC2731 is currently being investigated in Phase II stage of Clinical trial evaluation for the treatment of Asthma.
* AZD4604: AstraZeneca
AZD4604 is a potent and selective inhibitor of Janus kinase family member, JAK1, intended for inhaled add-on treatment of moderate to severe asthma, uncontrolled on standard of care. Due to the broad anti-inflammatory properties of JAK1 inhibition, AZD4604 is predicted to provide benefit to steroid sensitive and insensitive asthma endotypes, thereby offering a differentiation opportunity from existing biologics. It is currently being investigated in Phase II stage of Clinical trial evaluation for the treatment of Asthma.
* FB704A: Oneness Biotech Co., Ltd.
FB704A is a fully human monoclonal antibody that inhibits IL-6/IL-6R signaling pathway by neutralizing IL-6. FB704A (anti-IL-6 Ab) can reduce bronchial hyperresponsiveness as well as the Th1, Th2, and Th17 inflammatory responses of the respiratory tract, inhibit IL-6 classic- and trans-signaling pathways, and therefore have a chance of improving the symptoms of severe asthma (with high neutrophils) and severe mixed-granulocytic asthma. It is currently being investigated in Phase II stage of Clinical trial evaluation for the treatment of Asthma.
* ARO-RAGE: Arrowhead Pharmaceuticals
ARO-RAGE is designed to reduce production of the Receptor for Advanced Glycation End products (RAGE) as a potential treatment for various muco-obstructive and inflammatory pulmonary diseases. It is currently being investigated in Phase I stage of Clinical trial evaluation for the treatment of Asthma.
Learn more about Asthma Drugs opportunities in our groundbreaking Asthma Research and development projects @ Asthma Unmet Needs [https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Asthma Companies
GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Oneness Biotech Co., Ltd., Arrowhead Pharmaceuticals, Areteia Therapeutics, Jiangsu HengRui Medicine, SinoMab BioScience Ltd, Incyte Corporation, CSPC ZhongQi Pharmaceutical, Advagene Biopharma Co. Ltd., Beijing Kanova Biopharmaceutical, Inmunotek, Roche, Sanofi, ARS Pharmaceuticals, and others.
Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical
Asthma Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Discover the latest advancements in Asthma treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Asthma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Asthma Pipeline Report
* Coverage- Global
* Asthma Companies- GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Oneness Biotech Co., Ltd., Arrowhead Pharmaceuticals, Areteia Therapeutics, Jiangsu HengRui Medicine, SinoMab BioScience Ltd, Incyte Corporation, CSPC ZhongQi Pharmaceutical, Advagene Biopharma Co. Ltd., Beijing Kanova Biopharmaceutical, Inmunotek, Roche, Sanofi, ARS Pharmaceuticals , and others.
* Asthma Therapies- HSK31858, Dexpramipexole Dihydrochloride, Benralizumab, Dupilumab, Rocatinlimab, Mepolizumab , and others.
* Asthma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Asthma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and plans, read the full details of Asthma Pipeline on our website @ Asthma Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Asthma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Asthma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* GSK3511294: GlaxoSmithKline
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* TQC2731: Chia Tai Tianqing Pharmaceutical Group
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* ARO-RAGE: Arrowhead Pharmaceuticals
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Asthma Key Companies
* Asthma Key Products
* Asthma- Unmet Needs
* Asthma- Market Drivers and Barriers
* Asthma- Future Perspectives and Conclusion
* Asthma Analyst Views
* Asthma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=asthma-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/asthma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Asthma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND here
News-ID: 4000132 • Views: …
More Releases from ABNewswire
OEKO-TEX Certified Silk Pajamas: A Must for EU/US Retailers
Image: https://www.cnwonderfultextile.com/uploads/8dc07cf72c90f41409a216a935c816c1.jpg
Consumers today place greater value on safety, sustainability, and luxury in their purchases. OEKO-TEX certified silk pajamas perfectly meet these expectations, making them a lucrative choice for EU and US retailers. Women aged 25-45, who dominate over 40% of silk pajama sales, increasingly prefer certified products for their non-toxic materials. Recent trends also show households earning above $75,000 spending more on premium sleepwear, reflecting a shift toward sustainable luxury.…
Tips for Sourcing High-Quality Wood Pulp Napkin Tissue Paper Parent Rolls
Image: https://statics.mylandingpages.co/static/aaanxdmf26c522mpaaaaz2wwe7ppkact/image/649654f52b3c4a1d9c411943fcaa6954.webp
Sourcing the right wood pulp napkin tissue paper parent roll starts with understanding the best Raw Material For Making Tissue Paper [https://www.bincheng-paper.com/about-us/]. Buyers look for clear quality indicators like consistency and softness. Safety matters too, so they check for trusted suppliers. Many use Paper Tissue Mother Reels or a Mother Toilet Paper Roll to meet their needs.
Key Criteria for Sourcing Wood Pulp Napkin Tissue Paper Parent RollConsistency in Roll…
Seamless Knit Yoga Fabric: Revolutionizing Comfort for High-Intensity Wear
Image: https://statics.mylandingpages.co/static/aaanxdmf26c522mpaaaaz2wwe7ppkact/image/953d528294f848bcb57e743656e5a8cb.webp
Seamless Knit yoga fabric changes the workout experience for athletes and fitness enthusiasts. This advanced material eliminates skin irritation and delivers a smooth, second-skin feel. Users notice greater flexibility during high-intensity movements. > Many appreciate how this fabric supports the body without restricting motion or causing discomfort. Its design allows for continuous performance without distraction.
Key Takeaways
* Seamless Knit Yoga Fabric [https://www.suertetextile.com/yoga-fabric/] offers a smooth, second-skin feel by eliminating…
Single Use Assemblies Market to Hit USD 4.89 Billion by 2029 with 13.2% CAGR | M …
Browse 470 market data Tables and 58 Figures spread through 427 Pages and in-depth TOC on "Single Use Assemblies Market by Product (Bag (2D, 3D), Filtration, Bottle, Mixing, Tubing Assemblies), Solution (Customized, Standard), Modality (mAbs, Vaccines, CGT), Application (Filtration, Cell Culture, Storage, Transfer) - Global Forecasts to 2029
The global single-use assemblies market [https://www.marketsandmarkets.com/Market-Reports/single-use-assemblies-market-46226549.html?utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=singleuseassembliesmarket], valued at US$ 2.52 billion in 2023, is forecasted to grow at a robust CAGR of 13.2%,…
More Releases for Asthma
Asthma Treatment Market: Increase in Prevalence of Asthma and Rise in Awareness …
Transparency Market Research (TMR) has published a new report on the asthma treatment market for the forecast period of 2019–2027. According to the report, the global asthma treatment market was valued at ~US$ 25 Bn in 2018, and is projected to expand at a CAGR of ~2% from 2019 to 2027.
Read Report Overview - https://www.transparencymarketresearch.com/asthma-treatment-market.html
Overview
Asthma treatment involves two main types of medications: long-term asthma control medications and quick-relief (rescue) medications.
Asthma…
Anti-Asthma Drugs Market Factors Affecting Market Growth 2018 | Key Type of Asth …
To Track and Analyze Competitive Developments such as Joint Ventures, Strategic Alliances, Mergers and Acquisitions, New Product Developments, and Research and Developments Globally. The all things added in “Global Anti Asthma Drugs Market Research Report – Forecast to 2022” – Avail Prime Report to MRFR
Anti-Asthma Drugs Market - Overview
With the air pollution rising around the world, the number of asthma patients is also increasing. Therefore the market for the drugs…
Asthma-Pipeline Review H2 2017
ReportsWeb.com published “Asthma” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Asthma-Pipeline Review, H2 2017, provides an overview of the Asthma (Respiratory) pipeline landscape.
Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow…
Landmark Asthma Study Demonstrates Device Choice Determines Asthma Control
Monaghan Medical Corporation understands that for those with asthma, particularly children, choosing the device that best delivers their medication is an important consideration.
Plattsburgh, NY, USA -- Monaghan Medical Corporation understands that for those with asthma, particularly children, choosing the device that best delivers their medication is an important consideration. Research has shown that even when using the same metered-dose inhaler (MDI), not all valved holding chambers perform equally well.[1]
A landmark…
Asthma-Pipeline Review H2 2017
ReportsWeb.com published “Asthma” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Asthma-Pipeline Review, H2 2017, provides an overview of the Asthma (Respiratory) pipeline landscape.
Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow…
Asthma Therapeutics Market to 2020 - Personalized Treatment for Severe Asthma to …
Recent Research, a leading business intelligence provider, has released its latest research report: “Asthma Therapeutics Market to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations.”
The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR)…
